Valneva (VALN)
(Delayed Data from NSDQ)
$7.87 USD
+0.37 (4.93%)
Updated Aug 5, 2025 04:00 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VALN 7.87 +0.37(4.93%)
Will VALN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VALN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VALN
Valneva (VALN) Soars 17.4%: Is Further Upside Left in the Stock?
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study
VALN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cooper Companies Q1 Earnings Likely to Reflect Seasonal Trends
Favorable VLA1553-321 Phase 3 Study Results Boost VALN Stock
Chikungunya Vaccine Label Extension Call Likely to Support VALN Stock
Other News for VALN
Valneva (VALN) Partners with AGC Biologics for Shigella Vaccine Development
Valneva signs development, manufacturing agreement with AGC Biologics
AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's ...
MP Materials, CoreWeave, Trade Desk And Other Big Stocks Moving Higher On Tuesday
EMA Lifts Suspension on Valneva's (VALN) Chikungunya Vaccine for Seniors